- Home
- VRDN vs VCYT Comparison
VRDN vs VCYT Comparison
Compare VRDN & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | VCYT |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | VRDN | VCYT |
|---|---|---|
| Price | $32.11 | $44.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $41.17 | ★ $46.00 |
| AVG Volume (30 Days) | ★ 1.2M | 635.2K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $70,789,000.00 | ★ $495,141,000.00 |
| Revenue This Year | $26,257.62 | $16.46 |
| Revenue Next Year | $4.54 | $11.37 |
| P/E Ratio | ★ N/A | $113.82 |
| Revenue Growth | ★ 23340.07 | 16.41 |
| 52 Week Low | $9.90 | $22.61 |
| 52 Week High | $34.29 | $50.71 |
Technical Indicators
Market Signals| Indicator | VRDN | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 52.45 | 55.57 |
| Support Level | $29.63 | $40.29 |
| Resistance Level | $34.29 | $44.59 |
| Average True Range (ATR) | 1.35 | 1.93 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 59.29 | 60.02 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.